Trial 0S-00-15

Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer.

Type: Specimen Study
Phase: Not Applicable
Status: Open to Accrual
Treatments:
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Heinz Josef Lenz, M.D.
Other Trial Staff: Ramona Lujan, R.N., Jiayi Jiang, D.M., Henock Solomon, D.M.

Staff may log in to see study documents.

You may participate in this study if:

	Requirement
1	Histologically confirmed cancer that will be treated with 5-FU-based chemotherapy.
2	At least 18 years of age.
3	Prior chemotherapy is allowed. No prior 5-FU therapy is allowed, except when patients are treated with novel fluoropyrimidine compounds (xeloda or alimpta).
4	Must allow the use of their fresh frozen or paraffin-embedded tumor tissue that has been previously collected. Tumor tissue should be collected prior to the start of fluoropyrimidine therapy.
5	Signed informed consent.

You may not participate in this study if:

1	Limited amount of tumor tissue available for diagnostic purposes. The pathologists, Drs. Sherrod and Naritoku will make the decision whether there is sufficient material for this study.

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.